Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
申请人:Zheng Zhongli
公开号:US20070249682A1
公开(公告)日:2007-10-25
The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
The activated core approach to combinatorial chemistry: A selection of new core molecules
作者:Kent E. Pryor、Gerald W. Shipps、David A. Skyler、Julius Rebek
DOI:10.1016/s0040-4020(98)00139-2
日期:1998.4
Four new activated core molecules suitable for use in solution-phase combinatorial organic chemistry have been prepared. These molecules represent an attempt to further explore shape-space and increase the structural diversity of prepared libraries, as well as to incorporate recognition elements in the cores to increase the chances for interaction with biological targets. Demonstrations of deconvolution strategies used to simplify complex libraries and build individual molecular species based on the cores are also provided. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
HUNIG, SIEGFRIED;WEHNER, INGEBORG, SYNTHESIS,(1989) N, C. 552-554